bioAffinity Technologies, Inc. (BIAF)

The past six months have seen significant volatility in bioAffinity Technologies' stock price. As of March 26, 2026, the stock price was $4.73 per share, a 45.29% decline from March 24, 2025. There was a premarket surge on March 25, 2026, following the announcement of a live virtual physician roundtable on CyPath Lung integration. The stock surged 85% on March 23, 2026, due to an upbeat update on CyPath Lung's growth and a positive 2026 outlook. On March 13, 2026, the stock saw a dramatic surge of 98.13% to $2.12, driven by high trading volume and the announcement of record 2025 revenue and unit sales for CyPath® Lung. The company reported a total revenue of $6.2 million for 2025, down from $9.4 million in 2024, and a net loss for 2025 widened to $14.9 million from $9.0 million in 2024. The company's cash and cash equivalents increased to $6.5 million by December 31, 2025, from $1.1 million a year prior.

There is no explicit information available regarding demand seasonality for bioAffinity Technologies, Inc.'s products and services. Demand for CyPath® Lung is likely to be relatively stable throughout the year rather than subject to significant seasonal fluctuations. The reported growth in CyPath® Lung sales is attributed to factors such as increased adoption by physicians and clinics, peer-to-peer marketing, and growing awareness of the test, rather than seasonal patterns.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive, early-stage cancer diagnosis and targeted cancer treatments, particularly for lung diseases. The company operates within the Biotechnology sector and is primarily engaged in the In Vitro Diagnostics industry, as well as Commercial Physical & Biological Research. Its flagship product is CyPath® Lung, a noninvasive diagnostic test designed for the early detection of lung cancer, utilizing advanced flow cytometry and AI-driven algorithms to analyze cell populations in sputum samples. The company also focuses on developing diagnostics for other lung diseases, such as COPD and asthma, and advancing broad-spectrum cancer therapeutics.

bioAffinity Technologies, Inc. is headquartered in San Antonio, Texas, United States. While its primary operations and market reach are within the U.S., the company is actively building a global patent portfolio for its diagnostic platform and is exploring international licensing and distribution agreements to expand its footprint.

bioAffinity Technologies' brand reputation over the past year appears to be positively influenced by the strong performance and growth prospects of CyPath® Lung. Recent events contributing to a positive reputation include the announcement of a new case study on March 17, 2026, highlighting how CyPath® Lung provides actionable results. The company also garnered positive attention with its announcement of record 2025 revenue and unit sales for CyPath® Lung on March 13, 2026. Furthermore, the initiation of a large-scale longitudinal clinical study for its noninvasive CyPath® Lung cancer diagnostic on March 10, 2026, underscores its commitment to scientific validation and product advancement. The strategic decision to discontinue unprofitable pathology services has been framed as a move to streamline operations and focus on higher-value diagnostic testing.

bioAffinity Technologies, Inc. has a notable institutional ownership presence. As of March 26, 2026, there were 11 institutional owners and shareholders holding a total of 78,422 shares. Key institutional investors include Geode Capital Management, Llc, Northern Trust Corp, Citadel Advisors Llc, Two Sigma Securities, Llc, Citigroup Inc, Tower Research Capital LLC (TRC), IFP Advisors, Inc, Bank Of America Corp /de/, and Morgan Stanley. Other institutional investors who have recently purchased the company's stock include Sabby Management LLC, Sheaff Brock Investment Advisors LLC, Ground Swell Capital LLC, and Scientech Research LLC. The Vanguard Group, Inc. and L1 Capital Global Opportunities Master Fund, Ltd. are also listed among the top institutional holders. Insider ownership is reported at -0.01%.